Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03940248 | Proton Accelerated Partial Breast Irradiation(APBI) | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04882163 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 8 | Oct 5, 2021 | clinicaltrials |
| NCT04620473 | Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | withdrawn | Phase 2 | 0 | Shanghai Minimally Invasive Surgery CenterOTHER | 0 | Sep 28, 2021 | clinicaltrials |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer(AtezoVax) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02283944 | TMS Electrochemotherapy for Glioblastoma Multiforme | withdrawn | Phase 2 | 0 | University of AarhusOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT03563040 | Study of Photopheresis in the Treatment of Erythrodermic MF and SS(PROMPT) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer(PANDoRA) | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant(Immuno-POWER) | withdrawn | Phase 2 | 0 | Natalie CallendarOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT01915472 | A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | withdrawn | Phase 1 / Phase 2 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | withdrawn | Phase 1 / Phase 2 | 0 | NextCure, Inc.INDUSTRY | 0 | Aug 18, 2021 | clinicaltrials |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma(PLACARD) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Aug 17, 2021 | clinicaltrials |
| NCT04217720 | SNS-301 Monotherapy in High Risk MDS and CMML | withdrawn | Phase 2 | 0 | Sensei Biotherapeutics, Inc.INDUSTRY | 0 | Aug 12, 2021 | clinicaltrials |
| NCT03933761 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy(PRECISE) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Aug 10, 2021 | clinicaltrials |
| NCT00624312 | Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations | withdrawn | Phase 2 | 0 | University of LouisvilleOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT02127151 | A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer(PANDA) | withdrawn | Phase 2 | 0 | University College, LondonOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT01396733 | Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer(RALT) | withdrawn | Phase 2 | 0 | Asan Medical CenterOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04395092 | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | withdrawn | Phase 2 | 0 | Kiadis PharmaINDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04060407 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)(CINDI) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03053284 | Pasireotide in Hyperinsulinemic Hypoglycemia | withdrawn | Phase 2 | 0 | Montefiore Medical CenterOTHER | 0 | May 14, 2021 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT01802307 | Focal Therapy for Prostate Cancer | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT03586024 | Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Bausch Health Americas, Inc.INDUSTRY | 1 | May 7, 2021 | clinicaltrials |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | withdrawn | Phase 2 | 0 | The University of Hong KongOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04455958 | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 26, 2021 | clinicaltrials |
| NCT02497638 | LIpitor and biGuanide to Androgen Delay Trial(LIGAND) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04042506 | SBRT as a Vaccination for Metastatic Melanoma | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants(CheckMate 7UA) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 19, 2021 | clinicaltrials |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT02605694 | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | withdrawn | Phase 2 | 0 | SecuraBioINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03881735 | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03863301 | MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer(ABLATIVE-2) | withdrawn | Phase 2 | 0 | UMC UtrechtOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma(TheraBionics) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT00397761 | Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT02973711 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03758729 | Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 0 | Feb 16, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 6, 2021source: clinicaltrials